Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma
Abstract
One goal of precision medicine is to identify mutations within individual tumors to design targeted treatment approaches. This report details the use of genomic testing to select a targeted therapy regimen of erlotinib and rapamycin for a pediatric anaplastic oligodendroglioma refractory to standard treatment, achieving a 33‐month sustained response. Immunohistochemical analysis of total and phosphorylated protein isoforms showed abnormal signaling consistent with detected mutations, while revealing heterogeneity in per‐cell activation of signaling pathways in multiple subpopulations of tumor cells throughout the course of disease. This case highlights molecular features that may be relevant to designing future targeted treatments.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 01, 2020
- Source ID
- 10.1002/pbc.28750
Entities
People
- Adam John Esbenshade
- Asa A. Brockman
- Bret C. Mobley
- Devang Pastakia
- Laura C. Geben
- Rebecca A. Ihrie
- Rob Naftel
Organizations
- National Institute of General Medical Sciences
- National Institute of Neurological Disorders and Stroke
- United States Department of Defense
- Vanderbilt University